Arbogast Pharmaceuticals is developing a novel technology based on blood albumin’s inverse correlation with all cause mortality.

For every 10% decrease in albumin the incidence of death increases 24%. For instance, if 2 people are admitted to a hospital and they are 40 years old or older, the one with higher albumin has a better chance of coming out of the hospital alive. For people on kidney dialysis, mortality increases to 56% for every 10% decrease in albumin.

Arbogast Pharmaceuticals is founded on the theory that the reason for this inverse relationship between albumin and mortality is a cytoprotective activity associated with a specific form of albumin. Over the past 30 years, the founders have been investigating this albumin, called Toxicity Preventing Activity or TxPA, which neutralizes the toxicity of very low density lipoproteins (VLDL).

The theory of endothelial cell injury being a prominent part of atherosclerosis development has been proposed by medical scientists since at least the 1970’s. TxPA is in equilibrium with a second isoelectric form of albumin and this equilibrium depends on the amount of non-esterified fatty acids (NEFA) in the blood. If there are few NEFA, most of the albumin is in the protective form, if the molar ratio of NEFA to albumin is above 2, most of the albumin is in the non-protective form. Arbogast Pharmaceuticals holds international patents on a simplified assay to measure TxPA.

Recently the company identified a technology for increasing TxPA levels in humans, and a US patent has been filed.

The next step for Arbogast Pharmaceuticals is to conduct pilot studies to demonstrate that treatment will increase TxPA levels in the general population and to show that the increased TxPA decreases selected parameters of aging. If it can be demonstrated that treatment increases longevity, the paradigm of treating individual diseases such as heart disease, cancer, kidney disease and Alzheimer’s disease will be forever changed. Medicine’s focus will shift to preventing the diseases of old age and maintaining the health and disease resistance we had in our early adulthood.